Given their involvement in various malignancies, this study aimed to investigate the clinicopathological roles of MEG3 genetic variants, Ki-67, p53, and CK18 in the development of PitNETs, with the goal of clarifying their prognostic value, associations with tumor aggressiveness, and clinical characteristics, which may contribute to improved management of neuroendocrine tumors. The gene discussed is TP53; the disease is neoplasm.